Localization of EGFR Mutations in Non-small-cell Lung Cancer Tissues Using Mutation-specific PNA-DNA Probes

被引:2
作者
Shigeto, Hajime [1 ]
Miyata, Haruo [2 ]
Ashizawa, Tadashi [2 ]
Iizuka, Akira [2 ]
Kikuchi, Yasufumi [2 ]
Hozumi, Chikako [2 ]
Maeda, Chie [2 ]
Yamaguchi, Ken [3 ]
Yamamura, Shohei [1 ]
Akiyama, Yasuto [2 ]
机构
[1] Natl Inst Adv Ind Sci & Technol, Hlth & Med Res Inst, Takamatsu, Kagawa, Japan
[2] Shizuoka Canc Ctr, Immunotherapy Div, Res Inst, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan
[3] Shizuoka Canc Ctr, Nagaizumi, Shizuoka, Japan
关键词
PNA-DNA probe; EGFR mutation; tumor heterogeneity; multicolor immunofluorescence; image analysis software; PEPTIDE NUCLEIC-ACIDS; DISCRIMINATION; TRANSCRIPTION; GEFITINIB; TOOLS;
D O I
10.21873/cgp.20389
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Epidermal growth factor receptor (EGFR) signaling inhibitors are potent therapeutic agents for EGFR-mutant non-small-cell lung cancer, but the effects of such inhibitors on the localization of EGFR mutations in tumor tissues remain to be elucidated. Thus, a simple and efficient technology for the detection of mutations in tumor tissue specimens needs to be developed. Materials and Methods: Using an EGFR mutation-specific peptide nucleic acid (PNA)-DNA probe, the EGFR mutation-positive part of whole NSCLC tissues was visualized by immunofluorescence. Formalin-fixed paraffin-embedded sections obtained from A549, NCI-H1975, HCC827 and PC -9 tumors transplanted into nude mice were subjected to staining using PNA-DNA probes specific for the mRNA sequences producing the L858R, del E746-A750 and T790M mutations. Results: The probes for the L858R mutation showed intense positive staining in H1975 cells, and the probe for the del E746-A750 mutation exhibited positive staining specifically in HCC827 and PC-9 tumors. On the other hand, A549 tumors without EGFR mutation did not show any significant staining for any PNA-DNA probe. In combination staining, the addition of cytokeratin stain increased the positive staining rate of each PNA-DNA probe. In addition, the positive staining rate of the probes for the L858R mutation was comparable to that of the antibody to EGFR L858R mutated protein. Conclusion: PNA-DNA probes specific for EGFR mutations might be useful tools to detect heterogeneous mutant EGFR expression in cancer tissues and efficiently evaluate the effect of EGFR signaling inhibitors on tissues of EGFR-mutant cancer.
引用
收藏
页码:375 / 382
页数:8
相关论文
共 50 条
  • [31] Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summary
    Yang, James Chih-Hsin
    FUTURE ONCOLOGY, 2023, 19 (04) : 291 - 297
  • [32] Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?
    Rossi, Sabrina
    Di Noia, Vincenzo
    Tonetti, Laura
    Strippoli, Antonia
    Basso, Michele
    Schinzari, Giovanni
    Cassano, Alessandra
    Leone, Antonio
    Barone, Carlo
    D'Argento, Ettore
    FUTURE ONCOLOGY, 2018, 14 (10) : 919 - 926
  • [33] EGFR mutation positive stage IV non-small-cell lung cancer: treatment beyond progression
    Van Assche, Katrijn
    Ferdinande, Liesbeth
    Lievens, Yolande
    Vandecasteele, Katrien
    Surmont, Veerle
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [34] EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study
    de Mello, Ramon Andrade
    Pires, Filipa Soares
    Marques, Dania Sofia
    Oliveira, Julio
    Rodrigues, Ana
    Soares, Marta
    Azevedo, Isabel
    Peixoto, Ana
    Santos, Catarina
    Pinto, Carla
    Hespanhol, Venceslau
    Teixeira, Manuel R.
    Amaro, Teresina
    Queiroga, Henrique
    Araujo, Antonio
    TUMOR BIOLOGY, 2012, 33 (06) : 2061 - 2068
  • [35] EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Hastings, K.
    Yu, H. A.
    Wei, W.
    Sanchez-Vega, F.
    DeVeaux, M.
    Choi, J.
    Rizvi, H.
    Lisberg, A.
    Truini, A.
    Lydon, C. A.
    Liu, Z.
    Henick, B. S.
    Wurtz, A.
    Cai, G.
    Plodkowski, A. J.
    Long, N. M.
    Halpenny, D. F.
    Killam, J.
    Oliva, I
    Schultz, N.
    Riely, G. J.
    Arcila, M. E.
    Ladanyi, M.
    Zelterman, D.
    Herbst, R. S.
    Goldberg, S. B.
    Awad, M. M.
    Garon, E. B.
    Gettinger, S.
    Hellmann, M. D.
    Politi, K.
    ANNALS OF ONCOLOGY, 2019, 30 (08) : 1311 - 1320
  • [36] Association between EGFR Gene Mutation and Antioxidant Gene Polymorphism of Non-Small-Cell Lung Cancer
    Lin, Ching-Hsiung
    Yang, Po-Jen
    Lin, Sheng-Hao
    Yeh, Kun-Tu
    Tsao, Thomas Chang-Yao
    Chen, Yu-En
    Lin, Shu-Hui
    Yang, Shun-Fa
    DIAGNOSTICS, 2020, 10 (09)
  • [37] Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer
    Tokumo, Masaki
    Toyookaa, Shinichi
    Ichihara, Shuji
    Ohashi, Kadoaki
    Tsukuda, Kazunori
    Ichimura, Kouichi
    Tabata, Masahiro
    Kiura, Katsuyuki
    Aoe, Motoi
    Sano, Yoshifumi
    Date, Hiroshi
    Shimizu, Nobuyoshi
    LUNG CANCER, 2006, 53 (01) : 117 - 121
  • [38] Detection of EGFR Mutation in Tissue Samples of Non-small-cell Lung Cancer by a Fluorescence Polarization Assay
    Liu, Wenchao
    Li, Xiaofei
    Zhang, Zhipei
    Chen, Yanan
    Qiang, Shaoying
    Cheng, Hong
    Fan, Li
    Liang, Ping
    Zhang, Ju
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2012, 21 (03) : 138 - 142
  • [39] Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Sequist, L. V.
    Soria, J-C
    Goldman, J. W.
    Wakelee, H. A.
    Gadgeel, S. M.
    Varga, A.
    Papadimitrakopoulou, V.
    Solomon, B. J.
    Oxnard, G. R.
    Dziadziuszko, R.
    Aisner, D. L.
    Doebele, R. C.
    Galasso, C.
    Garon, E. B.
    Heist, R. S.
    Logan, J.
    Neal, J. W.
    Mendenhall, M. A.
    Nichols, S.
    Piotrowska, Z.
    Wozniak, A. J.
    Raponi, M.
    Karlovich, C. A.
    Jaw-Tsai, S.
    Isaacson, J.
    Despain, D.
    Matheny, S. L.
    Rolfe, L.
    Allen, A. R.
    Camidge, D. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18) : 1700 - 1709
  • [40] Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    BIOLOGY-BASEL, 2020, 9 (10): : 1 - 10